Develops cancer immunotherapies designed to activate inside tumors, including treatments that direct immune cells against cancer cells, for patients with cancer.
10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of…View ↗
Cancer immunotherapy has demonstrated compelling efficacy, including the ability to generate complete responses and the potential to…View ↗
T cell engagers are designed to redirect immune effector cells against cancer cells by simultaneously binding to a specific TAA expressed…View ↗
Xilio earns collaboration and license revenue from partners for rights to therapies and related development services. Contracts may provide upfront fees, development or regulatory milestones, and royalties on licensed-product sales; payments follow contract billing schedules, while revenue is tied to delivery of licenses or services.
10-K for FY2025, filed Mar 23, 2026The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company has entered into…View ↗
Performance Obligations. The promised goods or services in the Company’s arrangements typically consist of a license, or option to license…View ↗
The Company receives payments from its customers based on billing schedules established in each contract. Non-refundable upfront payments…View ↗
$43.8M
10-K for FY2025, filed Mar 23, 2026
$43.8M ↗
Pharmaceutical partners, including AbbVie and Gilead, work directly with Xilio through collaboration and license agreements for masked therapies and development work.
10-K for FY2025, filed Mar 23, 2026
No. It lost $35M in FY2025.
Pipeline expansion
The older report centered its named clinical candidates on tumor-activated cytokine and checkpoint-inhibitor therapies; the latest report also describes masked T-cell engager programs, including wholly owned candidates and a program with AbbVie.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology, or I-O, therapies with the goal…View ↗
Partnership model
The older report described Xilio as holding development and commercialization rights to its candidates while seeking partnerships; the latest describes licensing and collaboration arrangements with outside companies.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 23, 2026
Loading...